Methods and compositions for modulating responsiveness to corticosteroids

• US 6,054,487 A
• Filed: 03/18/1997
• Issued: 04/25/2000
• Est. Priority Date: 03/18/1997
• Status: Expired due to Fees

• Current Assignee: BASF AG (BASF SE)
• Original Assignee: BASF AG (BASF SE)
• Inventors: Carter, Adam, Sekut, Les, Tracey, Daniel E., Banerjee, Subhashis, Ghayur, Tariq
• Primary Examiner(s): Jarvis, William R. A.
• Application Number:
  US08/820,692
• Time in Patent Office: 1,134 Days
• Field of Search: 514/604, 514/602, 514/603
• US Class Current: 514/604
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/18 Sulfonamides compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Method for modulating responsiveness to corticosteroids in a subject are provided. In the method of the invention, an agent which antagonizes a factor that regulates production of IFN-γ in the subject is administered to the subject in combination with a corticosteroid such that responsiveness of the subject to the corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject. In one embodiment, the agent is an interferon-γ inducing factor (IGIF) antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. Other preferred agents include phosphodiesterase IV inhibitors and beta-2 agonists. The methods of the invention can be used in the treatment of a variety of inflammatory and immunological diseases and disorders. Pharmaceutical compositions comprising an agent which antagonizes a factor that regulates production of IFN-γ in a subject, a corticosteroid and a pharmaceutically acceptable carrier are also provided. A preferred composition comprises an ICE inhibitor, a corticosteroid and a pharmaceutically acceptable carrier.

Claims

1. A method for modulating responsiveness to a corticosteroid in a subject, comprising administering to the subject suffering from a condition normally responsive to corticosteroid therapy:

an interleukin-1 β

converting enzyme (ICE) inhibitor being administered at a dosage and by a route sufficient to inhibit production of IFN-γ

in the subject; and

a corticosteroid,

such that responsiveness of the subject to the corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject.

2. The method of claim 1, wherein the ICE inhibitor is an IFN-γ

inducing factor (IGIF) antagonist, the ICE inhibitor being administered at a dosage and by a route sufficient to inhibit IGIF activity in the subject.

3. The method of claim 1, wherein the corticosteroid is selected from the group consisting of cortisone, hydrocortisone, beclomethasone, flunisolide, prednisone, prednisolone, methylprednisolone, triamcinolone, deflazacort, betamethasone and dexamethasone.

4. The method of claim 1, wherein the subject is suffering from septic shock.

5. The method of claim 1, wherein the subject is suffering from Crohn'"'"'s disease.

6. The method of claim 1, wherein the subject is suffering from asthma.

7. The method of claim 1, wherein the subject is suffering from graft versus host disease or transplant rejection.

8. The method of claim 1, wherein the subject is suffering from an autoimmune disease or disorder.

9. The method of claim 1, wherein the subject is suffering from an immunoinflammatory disease or disorder selected from the group consisting of asthma, adult respiratory distress syndrome, systemic lupus erythematosus, inflammatory bowel disease, Crohn'"'"'s disease, ulcerative colitis, multiple sclerosis, insulin-dependent diabetes mellitus, autoimmune arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, inflammatory pulmonary syndrome, pemphigus vulgaris, idiopathic thrombocytopenic purpura, autoimmune meningitis, myasthenia gravis, autoimmune thyroiditis, dermatitis, atopic dermatitis, eczematous dermatitis, psoriasis, Sjogren'"'"'s Syndrome, keratoconjunctivitis sicca secondary to Sjogren'"'"'s Syndrome, alopecia areata, allergic responses due to arthropod bite reactions, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, drug eruptions, Stevens-Johnson syndrome, leprosy reversal reactions, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener'"'"'s granulomatosis, chronic active hepatitis, Graves ophthalmopathy, primary biliary cirrhosis, uveitis posterior and interstitial lung fibrosis.

10. The method of claim 1, wherein the subject is suffering from an acute inflammatory disorder.

11. The method of claim 1, wherein the subject is suffering from a chronic inflammatory disorder.

12. The method of claim 1, wherein the ICE inhibitor and corticosteroid are administered such that steroid resistance in the subject is reversed, as compared to when a corticosteroid alone is administered to the subject.

13. The method of claim 1, wherein the ICE inhibitor and corticosteroid are administered such that steroid sensitivity in the subject is increased, as compared to when a corticosteroid alone is administered to the subject.

14. The method of claim 1, wherein the ICE inhibitor and the corticosteroid are administered to the subject according to a schedule that reduces the dosage of the corticosteroid over time and e method ameliorates a steroid rebound effect associated with administration of reduced dosages of the corticosteroid.

35. A method of claim 9, wherein the subject is suffering from an immunoinflammatory disease or disorder selected from the group consisting of pemphigus vulgaris, dermatitis, atopic dermatitis, eczematous dermatitis, psoriasis, alopecia areata, allergic responses due to arthropod bite reactions, cutaneous lupus erythematosus, scleroderma, vaginitis, drug eruptions, Stevens-Johnson syndrome, leprosy reversal reactions, and erythema nodosum leprosum.

36. A method of claim 9, wherein the subject is suffering from an immunoinflammatory disease or disorder selected from the group consisting of multiple sclerosis, autoimmune arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, autoimmune meningitis, myasthenia gravis and allergic encephalomyelitis.

37. A method of claim 9, wherein the subject is suffering from an immunoinflammatory disease or disorder selected from the group consisting of systemic lupus erythematosus, inflammatory bowel disease, Crohn'"'"'s disease, ulcerative colitis, insulin-dependent diabetes mellitus, aphthous ulcer, proctitis, Wegener'"'"'s granulomatosis, chronic active hepatitis, and primary biliary cirrhosis.

38. A method of claim 9, wherein the subject is suffering from an immunoinflammatory disease or disorder selected from the group consisting of iritis, conjunctivitis, keratoconjunctivitis, autoimmune uveitis, Graves ophthalmopathy, and uveitis posterior.

39. A method of claim 9, wherein the subject is suffering from an immunoinflammatory disease or disorder selected from the group consisting of idiopathic thrombocytopenic purpura, autoimmune thyroiditis, Sjogren'"'"'s Syndrome, keratoconjunctivitis sicca secondary to Sjogren'"'"'s Syndrome, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, and polychondritis.

40. The method of claim 9, wherein the subject is suffering from an immunoinflammatory disease or disorder selected from the group consisting of asthma, adult respiratory distress syndrome, inflammatory pulmonary syndrome, and interstitial lung fibrosis.

15. A method for modulating responsiveness to corticosteroids in a subject, comprising administering to the subject suffering from a condition normally responsive to corticosteroid therapy,

an interleukin-1 β

converting enzyme (ICE) inhibitor; and

a corticosteroid,

such that responsiveness of the subject to the corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject.

16. The method of claim 15, wherein the corticosteroid is selected from the group consisting of cortisone, hydrocortisone, beclomethasone, flunisolide, prednisone, prednisolone, methylprednisolone, triamcinolone, deflazacort, betamethasone and dexamethasone.

17. The method of claim 15, wherein the subject is suffering from septic shock.

18. The method of claim 15, wherein the subject is suffering from Crohn'"'"'s disease.

19. The method of claim 15, wherein the subject is suffering from asthma.

20. The method of claim 15, wherein the subject is suffering from graft versus host disease or transplant rejection.

21. The method of claim 15, wherein the subject is suffering from an autoimmune disease or disorder.

22. The method of claim 15, wherein the subject is suffering from an immunoinflammatory disease or disorder selected from the group consisting of asthma, adult respiratory distress syndrome, systemic lupus erythematosus, inflammatory bowel disease, Crohn'"'"'s disease, ulcerative colitis, multiple sclerosis, insulin-dependent diabetes mellitus, autoimmune arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, inflammatory pulmonary syndrome, pemphigus vulgaris, idiopathic thrombocytopenic purpura, autoimmune meningitis, myasthenia gravis, autoimmune thyroiditis, dermatitis, atopic dermatitis, eczematous dermatitis, psoriasis, Sjogren'"'"'s Syndrome, keratoconjunctivitis sicca secondary to Sjogren'"'"'s Syndrome, alopecia areata, allergic responses due to arthropod bite reactions, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, drug eruptions, Stevens-Johnson syndrome, leprosy reversal reactions, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener'"'"'s granulomatosis, chronic active hepatitis, Graves ophthalmopathy, primary biliary cirrhosis, uveitis posterior and interstitial lung fibrosis.

23. The method of claim 15, wherein the subject is suffering from an acute inflammatory disorder.

24. The method of claim 15, wherein the subject is suffering from a chronic inflammatory disorder.

25. The method of claim 24, wherein the ICE inhibitor and the corticosteroid are administered such that steroid resistance in the subject is reversed, as compared to when a corticosteroid alone is administered to the subject.

26. The method of claim 24, wherein the ICE inhibitor and the corticosteroid are administered such that steroid sensitivity in the subject is increased, as compared to when a corticosteroid alone is administered to the subject.

27. The method of claim 24, wherein the ICE inhibitor and the corticosteroid are administered to the subject according to a schedule that reduces the dosage of the corticosteroid over time and the method ameliorates a steroid rebound effect associated with administration of reduced dosages of the corticosteroid.

41. A method of claim 22, wherein the subject is suffering from an immunoinflammatory disease or disorder selected from the group consisting of pemphigus vulgaris, dermatitis, atopic dermatitis, eczematous dermatitis, psoriasis, alopecia areata, allergic responses due to arthropod bite reactions, cutaneous lupus erythematosus, scleroderma, vaginitis, drug eruptions, Stevens-Johnson syndrome, leprosy reversal reactions, and erythema nodosum leprosum.

42. A method of claim 22, wherein the subject is suffering from an immunoinflammatory disease or disorder selected from the group consisting of mutiple sclerosis, autoimmune arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, autoimmune meningitis, myasthenia gravis and allergic encephalomyelitis.

43. A method of claim 22, wherein the subject is suffering from an innumoinflammatory disease or disorder selected from the group consisting of systemic lupus erythematosus, inflammatory bowel disease, Crohn'"'"'s disease, ulcerative colitis, insulin-dependent diabetes mellitus, aphthous ulcer, procitis, Wegener'"'"'s granulomatosis, chronic active hepatitis, and primary biliary cirrhosis.

44. A method of claim 22, wherein the subject is suffering from an inflammatory disease or disorder selected from the group consisting of ireitis, conjunctivitis, keratoconjunctivitis, autoimmune eveitis, Graves ophthalmopathy, and uveitis posterior.

45. A method of claim 22, wherein the subject is suffering from an immunoinflammatory disease or disorder selected from the group consisiting of idiopathic thrombocytopenic purpura, autoimmune thyroiditis, Sjogren'"'"'s Syndrome, keratoconjunctivitis sicca secondary to Sjogren'"'"'s Syndrome, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, and polychondritis.

46. The method of claim 22, wherein the subject is suffering from an immunoinflammatory disease or disorder selected from the group consisting of asthma, adult respiratory distress syndrome, inflammatory pulmonary syndrome, and interstitial lung fibrosis.

28. A method for modulating responsiveness to a corticosteroid in a subject, comprising:

selecting a subject in need of modulation of responsiveness to a corticosteroid, wherein the subject suffers from a condition normally responsive to corticosteroid therapy; and

administering to the subject an interleukin-1 β

converting enzyme (ICE) inhibitor which antagonizes a factor that regulates production of interferon (IFN-γ

) in the subject, the ICE inhibitor being administered at a dosage and by a route sufficient to inhibit production of IFN-γ

in the subject,

such that responsiveness of the subject to a corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject.

29. The method of claim 28, wherein the subject is resistant to a corticosteroid prior to administration of the ICE inhibitor.

30. The method of claim 28, wherein the subject is responsive to a corticosteroid prior to administration of the ICE inhibitor but exhibits increased sensitivity to the corticosteroid after administration of the ICE inhibitor.

31. The method of claim 28, wherein treatment of the subject with a corticosteroid is to be stopped and administration of the ICE inhibitor ameliorates a steroid rebound effect in the subject.

32. The method of claim 28, wherein the ICE inhibitor is an IFN-γ

inducing factor (IGIF) antagonist, the ICF inhibitor being administered at a dosage and by a route sufficient to inhibit IGIF activity in the subject.

33. A method for modulating responsiveness to corticosteroids in a subject comprising administering to the subject suffering from a condition normally responsive to corticosteroid therapy:

an interleukin-1β

converting enzyme (ICE) inhibitor compound having the structure of Formula I;

##STR6## wherein R¹ is hydrogen, C₁ -C₆ alkyl, or benzyl;

R² is --CHO, --COR^a, or --CN;

each R^a is independently hydrogen or C₁ -C₆ alkyl;

X is a bond, CH₂, CHR⁵, NH, NR⁵, or O;

R³ is aryl, substituted-aryl, heteroaryl, substituted-heteroaryl, cycloalkyl, substituted-cycloalkyl, heterocycle, or substituted-heterocycle;

Y is absent, NR⁵, CO, S, O, SO₂, --O(CHR⁵)_n --, CHR⁵, NR⁵ CO, NC(O)R⁵, CONR⁵, OCHR⁵, CHR⁵ O, SCHR⁵, CHR⁵ S, SO₂ NR⁵, C₁ -C₆ alkyl, NR⁵ SO₂, CH₂ CHR⁵, CHR⁵ CH₂, COCH₂, or CH₂ CO;

R⁴ is absent, aryl, substituted-aryl, C₁ -C₈ alkyl, heteroaryl, substituted-heteroaryl, cycloalkyl, C₁ -C₆ alkyl, substituted-cycloalkyl, heterocycloalkyl, or substituted-heterocycloalkyl;

each R⁵ is independently hydrogen, C₁ -C₆ alkyl, aryl, --(CH₂)_n aryl, or --(CH₂)_n cycloalkyl;

each n is independently 0 to 5, m is 1 or 2, and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof; and

a corticosteroid,

such that responsiveness of the subject to the corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject.

34. A method for modulating responsiveness to a corticosteroid in a subject, comprising:

selecting a subject in need of modulation of responsiveness to a corticosteroid, wherein the subject suffers from a condition normally responsive to corticosteroid therapy; and

administering to the subject an interleukin-1β

converting enzyme (ICE) inhibitor compound having The structure of Formula I;

##STR7## wherein R¹ is hydrogen, C₁ -C₆ alkyl, or benzyl;

R² is --CHO, --COR^a, or --CN;

each R^a is independently hydrogen or C₁ -C₆ alkyl;

X is a bond, CH₂, CHR⁵, NH, NR⁵, or O;

R³ is aryl, substituted-aryl, heteroaryl, substituted-heteroaryl, cycloalkyl, substituted-cycloalkyl, heterocycle, or substituted-heterocycle;

Y is absent, NR⁵, CO, S, O, SO₂, --O(CHR⁵)_n --, CHR5, NR⁵ CO, NC(O)R⁵, CONR⁵, OCHR⁵, CHR⁵ O, SCHR⁵, CHR⁵ S, SO₂ NR⁵, C₁ -C₆ alkyl, NR⁵ SO₂, CH₂ CHR⁵, CHR⁵ CH₂, COCH₂, or CH₂ CO;

R⁴ is absent, aryl, substituted-aryl, C₁ -C₈ alkyl, heteroaryl, substituted-heteroaryl, cycloalkyl, C₁ -C₆ alkyl, substituted-cycloalkyl, heterocycloalkyl, or substituted-heterocycloalkyl;

each R⁵ is independently hydrogen, C₁ -C₆ alkyl, aryl, --(CH₂)_n aryl, or --(CH₂)_n cycloalkyl;

each n is independently 0 to 5, m is 1 or 2, and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof,

the compound being administered at a dosage and by a route sufficient to inhibit production of IFN-γ

in the subject,

such that responsiveness of the subject to a corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject.